Oncology

Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.

Craig Portell, MD, of the University of Virginia Health System, highlights some of the latest and most exciting treatments in non-Hodgkin's lymphoma, including CAR-T therapies and targeted therapies such as venetoclax.

A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies.

A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology examined retrospective surveillance data in 3 different cancers: non-small cell lung cancer, head and neck cancer, and colorectal cancer.

As practices participating in the Oncology Care Model progress in their practice transformation they run into some challenges, such as how to properly analyze claims data, and see early successes, such as improved patient experience, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

One of the kickoff sessions on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, was a lively discussion on ensuring that the data used to inform patient care and create healthcare policies holds value.

A late afternoon extended education session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, was a discussion on the state-of-the-art uses for immunotherapy in the management of non-small cell lung cancer (NSCLC).

Checkpoint inhibitors have begun to revolutionize bladder cancer treatments, but the benefits in prostate cancer are a little less clear at this point, explained Daniel George, MD, of the Duke Cancer Insitute.

According to a recent study, women who live in a highly segregated white community are more likely to receive a late-stage diagnosis of breast cancer.

Analysis of data available within a national hospital-based registry showed that the diagnosis of stage I disease increased for female breast cancer, colorectal cancer, and lung cancer following implementation of the Affordable Care Act (ACA).

A new study finds that bariatric surgery can have beneficial effects for women beyond just weight loss: it was also associated with lower risk of female-specific cancers, like breast or ovarian cancer.

According to the study, to be presented at the 2017 American Society of Clinical Oncology Annual Meeting, vaccination resulted in an 88% overall reduction in vaccine-type infections and a 100% reduction among men, in the young adult population.

Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene now have a first-line option: ceritinib.

The findings are the results of a collaborative study conducted at various cancer institutions across the United States, which evaluated the impact of following the 2012 American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors.

This week, the top managed care news included the Congressional Budget Office's new score for the American Health Care Act; the White House released its fiscal year 2018 budget; and a cancer drug approval that is a first for the FDA.

Based on the results of the phase 2 ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma, Kite Pharma has submitted for, and received, a priority review for its chimeric antigen receptor (CAR)-T cell treatment, axicabtagene ciloleucel.

Amy J. Reed, MD, died 4 years following her surgery that used a power morcellator to remove her uterus, resulting in the spread of a hidden cancer.

The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.

A study published in the Annals of Internal Medicine reports that black Medicare enrollees are less likely to receive colonoscopy from more highly-rated physicians, which could increase their risk for interval colorectal cancer.

Comprehensive genetic testing using multigene testing panels for prostate cancer can arm genetic counselors with the information they need to guide precision therapy, even in men with early stage disease but a strong family history of the disease.

Although each individual rare cancer affects a small percentage of patients, the collective group of 181 rare cancers is responsible for significant disease burden in the United States.

Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology research where he anticipates significant advances will be made in coming years.

A research study by scientists at Yale and Johns Hopkins has found that surgeons are influenced by their peers when it comes to the use of new imaging technologies.

A year-long collaboration between a health consultancy and a think tank has resulted in the first draft of a framework that considers the value of healthcare services from the patient’s perspective.

The National Cancer Moonshot initiative called for tearing down the silos that prevent researchers from sharing information. FDA’s Richard Pazdur, MD, is doing just that-through the new Oncology Center of Excellence. Pazdur shares how the center will work in a special issue of Evidence-Based Oncology, publication of The American Journal of Managed Care.®

An overview of the FDA's Oncology Center of Excellence-a collaborative approach to the clinical approval process.

At the The American Journal of Managed Care®'s Spring 2017 Oncology Stakeholders Summit, the discussion touched off-label communication, the evolving clinical trial design, and healthcare reform, all while ensuring care is patient-centered.

A new study suggests that tai chi may be as effective as traditional therapies at reducing insomnia in breast cancer survivors.

Exercise is important for wellness and can also improve patient outcomes. The question remains: who should take the lead in recommending an exercise routine for patients with cancer?